A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
about
Digitalis for treatment of heart failure in patients in sinus rhythmPhosphodiesterase III inhibitors for heart failureDigitalis for treatment of heart failure in patients in sinus rhythmStatistical Methods for Cardiovascular ResearchersAgents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyondCytokines as new treatment targets in chronic heart failureTreating critical illness: the importance of first doing no harmDesigning phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failureCurrent and Potential Therapeutic Strategies for Hemodynamic Cardiorenal SyndromeRight ventricular adaptation and failure in pulmonary arterial hypertension.Emerging drugs in peripheral arterial diseaseFutility approaches to interim monitoring by data monitoring committees.Cilostazol: treatment of intermittent claudication.Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach.Inotropes do not increase mortality in advanced heart failureCa2+-independent positive molecular inotropy for failing rabbit and human cardiac muscle by alpha-myosin motor gene transfer.Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene TherapyChronic inotropic therapy in end-stage heart failure.Therapeutic range of digoxin's efficacy in heart failure: what is the evidence?Hospital variation in intravenous inotrope use for patients hospitalized with heart failure: insights from Get With The Guidelines.Omecamtiv Mecarbil, a Cardiac Myosin Activator, Increases Ca2+ Sensitivity in Myofilaments With a Dilated Cardiomyopathy Mutant Tropomyosin E54K.Major beta blocker mortality trials in chronic heart failure: a critical review.The rational use of beta-adrenoceptor blockers in the treatment of heart failure. The changing face of an old therapySalt intake is associated with inflammation in chronic heart failure.Tailored therapy to hemodynamic goals for advanced heart failure.Clinical overview of the novel inotropic agent toborinone.Digitalis for treatment of congestive heart failure in patients in sinus rhythm.Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure.Crossovers between functional and proliferative signaling: key to understanding the pathophysiology and management of heart failure.Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan?Heart failure: a hemodynamic disorder complicated by maladaptive proliferative responses.New predictive models of heart failure mortality using time-series measurements and ensemble modelsDrug therapy in chronic heart failure.The evolving role of nesiritide in advanced or decompensated heart failure.Reversal of isoflurane-induced depression of myocardial contraction by nitroxyl via myofilament sensitization to Ca2+Selection of endpoints for heart failure clinical trials.Guidelines for acute decompensated heart failure treatment.Regulation of cAMP homeostasis by the efflux protein MRP4 in cardiac myocytes.
P2860
Q24194992-ABB5E522-8724-4DA2-965E-D7B946117100Q24244978-B0A19F5D-F228-4125-AF4D-EE7ED0328224Q24247158-4F6C3DBB-53D5-4C24-80ED-42F0D4CCE121Q24289000-2F2A73B2-8796-4A2C-A63E-79E31355BF9FQ24645066-8DEB8F45-42A8-43D5-90B1-792B817A7544Q24799394-E2EDBA86-2984-4767-8F2D-8EC6FB36499CQ24813804-2EB25163-E42D-4BF2-8268-430DA13008FCQ26749027-0FD83A6B-4076-4CD3-9C01-FD03265DA547Q26753862-3E12E851-BC33-45BE-979F-5A24E45272EDQ27318422-E1C3BD12-5ED7-4D3A-AE18-A19A3A7309ACQ28195408-80D9019A-6CFD-4FE0-B443-8E1F9F5A2B7BQ31085620-3E63EF6C-BFD2-4A28-B057-BD71A45563C5Q31989672-CC6E068D-CADA-4BEE-B983-655B02700D36Q33656552-02A4A5EC-BBF9-4389-B431-48D5C1066D7CQ33685748-E3A59372-A7DC-4C68-82C9-4FC2B1AE287CQ33724399-907C2EC9-2A2B-4DEE-91BE-9F0FA0869370Q33728779-76482295-F501-4894-BC07-9443739D073DQ33735360-9DD96631-1A24-4AE3-881A-D1842BF976DBQ33747147-63636193-9676-4FAB-9AA1-3842113CE870Q33764415-E694D027-9B1F-4BE0-AA5F-A1ABCA1873B5Q33768442-CFA41F17-D255-4C9A-A7BD-AE80CDD1BCCAQ33780871-68C4269C-EE41-45B9-A0A9-6AD2FDF0166AQ33801164-9AA8C067-D522-499E-B778-6DC9C02030AEQ33942433-A15FE644-300D-4EBF-8F3C-11086BE44530Q33997965-BBF7283A-5DEC-4738-A3B0-23D9DD252BA9Q34074862-D7F1CB9E-E70F-4D52-B525-34009B46FC0FQ34202664-2FED9563-99EA-4F57-BAA6-375FDF2E2D3BQ34232063-22FCBAB2-BB28-4500-8DCD-C838B8D92B74Q34518494-8A50410D-50A9-4300-B9C1-1E821694D66CQ34584204-3923397E-CFFF-4697-A939-510FCBDF68D0Q34687809-42246E60-3F72-4CBD-8777-D50C90FE3B34Q35057072-FC845A82-0315-4A19-8183-FA28648621C3Q35136114-FFF07701-DD77-44D0-9012-E54DE9961948Q35138058-70977017-023A-47F1-9005-A9E6DD1F3553Q35518236-0B08DA18-C43A-4820-962B-33DE5E8C277FQ35574016-27306604-17FD-4010-B1AE-EBF8B212F840Q35579502-6584FDF7-7E5D-4786-B459-B9249B287BD9Q35607862-3FE18EE4-2101-4B4B-BB42-EA32258D484DQ35675111-872EFBAA-66F2-44BB-B2CC-C7143FCD9DC8Q35787715-B92C254D-7578-44CF-B35F-9571D2E85625
P2860
A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators.
description
1998 nî lūn-bûn
@nan
1998 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1998 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
1998年の論文
@ja
1998年論文
@yue
1998年論文
@zh-hant
1998年論文
@zh-hk
1998年論文
@zh-mo
1998年論文
@zh-tw
1998年论文
@wuu
name
A dose-dependent increase in m ...... snarinone Trial Investigators.
@ast
A dose-dependent increase in m ...... snarinone Trial Investigators.
@en
A dose-dependent increase in m ...... snarinone Trial Investigators.
@nl
type
label
A dose-dependent increase in m ...... snarinone Trial Investigators.
@ast
A dose-dependent increase in m ...... snarinone Trial Investigators.
@en
A dose-dependent increase in m ...... snarinone Trial Investigators.
@nl
prefLabel
A dose-dependent increase in m ...... snarinone Trial Investigators.
@ast
A dose-dependent increase in m ...... snarinone Trial Investigators.
@en
A dose-dependent increase in m ...... snarinone Trial Investigators.
@nl
P2093
P1476
A dose-dependent increase in m ...... snarinone Trial Investigators.
@en
P2093
Goldstein SO
Gottlieb SO
Greenberg BH
McGrew F 3rd
P304
P356
10.1056/NEJM199812173392503
P407
P577
1998-12-01T00:00:00Z